Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries

References

• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–1203.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.
   PubMed Web of Science ®Google Scholar
• Javitt DC. Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overview. Am J Manag Care. 2014;20(8 Suppl):S160–S5.
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-an overview. JAMA Psychiatry. 2020;77(2):201–210.
   PubMed Web of Science ®Google Scholar
• Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry. 2006;11(1):11–17.
   PubMed Web of Science ®Google Scholar
• Grover S, Chakrabarti S, Kulhara P, et al. Clinical practice guidelines for management of schizophrenia. Indian J Psychiatry. 2017;59(Suppl 1):S19–S33.
   PubMedGoogle Scholar
• Keepers, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177:868–872.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. 2014. [cited 2022 Jul]. Available from https://www.nice.org.uk/guidance/cg178.
   Google Scholar
• Krogmann A, Peters L, von Hardenberg L, et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24(S1):38–69.
   PubMedGoogle Scholar
• Cho SJ, Kim J, Kang YJ, et al. Annual prevalence and incidence of schizophrenia and similar psychotic disorders in the Republic Of Korea: a national health insurance data-based study. Psychiatry Investig. 2020;17(1):61–70.
   PubMed Web of Science ®Google Scholar
• Cooper L, Peters L, Andrews G. Validity of the composite international diagnostic interview (CIDI) psychosis module in a psychiatric setting. J Psychiatr Res. 1998;32(6):361–368.
   PubMed Web of Science ®Google Scholar
• Crespo-Facorro B, Such P, Nylander AG, et al. The burden of disease in early schizophrenia – a systematic literature review. Curr Med Res Opin. 2021;37(1):109–121.
   PubMed Web of Science ®Google Scholar
• Christensen MK, Lim CCW, Saha S, et al. The cost of mental disorders: a systematic review. Epidemiol Psychiatr Sci. 2020;29:e161.
   PubMed Web of Science ®Google Scholar
• Pilon D, Patel C, Lafeuille MH, et al. Prevalence, incidence and economic burden of schizophrenia among medicaid beneficiaries. Curr Med Res Opin. 2021;37(10):1811–1819.
   PubMed Web of Science ®Google Scholar
• Zhang W, Amos TB, Gutkin SW, et al. A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States. Clinicoecon Outcomes Res. 2018;10:309–320.
   PubMed Web of Science ®Google Scholar
• Loftus J, Camacho-Hubner C, Hey-Hadavi J, et al. Targeted literature review of the humanistic and economic burden of adult growth hormone deficiency. Curr Med Res Opin. 2019;35(6):963–973.
   PubMed Web of Science ®Google Scholar
• Schultz NM, Bhardwaj S, Barclay C, et al. Global burden of dry age-related macular degeneration: a targeted literature review. Clin Ther. 2021;43(10):1792–1818.
   PubMed Web of Science ®Google Scholar
• Dussart C, Gelas J, Geffroy L, et al. Medico-economic study of pain in an emergency department: a targeted literature review. J Mark Access Health Policy. 2019;7(1):1659099.
   PubMedGoogle Scholar
• Yeh YC, Yu X, Zhang C, et al. Literature review and economic evaluation of oral and intramuscular ziprasidone treatment among patients with schizophrenia in China. Gen Psychiatr. 2018;31(3):e100016.
   PubMed Web of Science ®Google Scholar
• Németh B, Fasseeh A, Molnár A, et al. A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2018;18(3):267–275.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Boonen A, de Wit M, et al. Cost assessment of health interventions and diseases. RMD Open. 2020;6(3):e001287.
   PubMedGoogle Scholar
• Tai BB, Bae YH, Le QA. A systematic review of health economic evaluation studies using the patient’s perspective. Value Health. 2016;19(6):903–908.
   PubMed Web of Science ®Google Scholar
• Anggraeni M, Gupta J, Verrest HJLM. Cost and value of stakeholders participation: a systematic literature review. Environ Sci Policy. 2019;101:364–373.
   Web of Science ®Google Scholar
• Vieta A, Badia X, Sacristán JA. A systematic review of patient-reported and economic outcomes: value to stakeholders in the decision-making process in patients with type 2 diabetes mellitus. Clin Ther. 2011;33(9):1225–1245.
   PubMed Web of Science ®Google Scholar
• Xu L, Xu T, Tan W, et al. Household economic burden and outcomes of patients with schizophrenia after being unlocked and treated in rural China. Epidemiol Psychiatr Sci. 2019;29:e81.
   PubMed Web of Science ®Google Scholar
• Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10:23–41.
   PubMed Web of Science ®Google Scholar
• Oliva-Moreno J, Lopez-Bastida J, Osuna-Guerrero R, et al. The costs of schizophrenia in Spain. Eur J Health Econ. 2006;7(3):182–188.
   PubMedGoogle Scholar
• Guest JF, Cookson RF. Cost of schizophrenia to UK society. An incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics. 1999;15(6):597–610.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66(9):1122–1129.
   PubMed Web of Science ®Google Scholar
• Frey S. The economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matching. Eur Psychiatry. 2014;29(8):479–489.
   PubMed Web of Science ®Google Scholar
• Desai PR, Lawson KA, Barner JC, et al. Estimating the direct and indirect costs for community-dwelling patients with schizophrenia. J Pharm Health Ser. Res. 2013;4(4):187–194.
   Google Scholar
• Heider D, Bernert S, König HH, et al. Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom - findings from the European schizophrenia cohort (EuroSC). Eur Psychiatry. 2009;24(4):216–224.
   PubMed Web of Science ®Google Scholar
• Barbosa WB, Costa JO, de Lemos LLP, et al. Costs in the treatment of schizophrenia in adults receiving atypical antipsychotics: an 11-year cohort in Brazil. Appl Health Econ Health Policy. 2018;16(5):697–709.
   PubMed Web of Science ®Google Scholar
• Anderson M, Revie CW, Quail JM, et al. The effect of socio-demographic factors on mental health and addiction high-cost use: a retrospective, population-based study in Saskatchewan. Can J Public Health. 2018;109(5–6):810–820.
   PubMed Web of Science ®Google Scholar
• Jerrell JM, McIntyre RS, Tripathi A. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. Clin Schizophr Relat Psychoses. 2010;4(3):161–168.
   PubMedGoogle Scholar
• Kearns B, Cooper K, Cantrell A, et al. Schizophrenia treatment with second-generation antipsychotics: a multi-country comparison of the costs of cardiovascular and metabolic adverse events and weight gain. Neuropsychiatr Dis Treat. 2021;17:125–137.
   PubMed Web of Science ®Google Scholar
• Abouzaid S, Tian H, Zhou H, et al. Economic burden associated with extrapyramidal symptoms in a Medicaid population with schizophrenia. Community Ment Health J. 2014;50(1):51–58.
   PubMed Web of Science ®Google Scholar
• Kadakia A, Brady BL, Dembek C, et al. The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population. J Med Econ. 2022;25(1):87–98.
   PubMed Web of Science ®Google Scholar
• Rice DP, Miller LS. The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, editors. Handbook of mental health economics and health policy. Volume 1: schizophrenia. Oxford: Wiley; 1996. p. 321–334.
   Google Scholar
• Zhu B, Ascher-Svanum H, Faries DE, et al. Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry. 2008;8:72.
   PubMed Web of Science ®Google Scholar
• Goeree R, O'Brien BJ, Goering P, et al. The economic burden of schizophrenia in Canada. Can J Psychiatry. 1999;44(5):464–472.
   PubMed Web of Science ®Google Scholar
• Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005;21(12):2017–2028.
   PubMed Web of Science ®Google Scholar
• Marcellusi A, Fabiano G, Viti R, et al. Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis. BMJ Open. 2018;8(2):e018359.
   PubMed Web of Science ®Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30(2):279–293.
   PubMed Web of Science ®Google Scholar
• Tarricone R, Gerzeli S, Montanelli R, et al. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Interdisciplinary study group on the economic impact of schizophrenia. Health Policy. 2000;51(1):1–18.
   PubMed Web of Science ®Google Scholar
• Haro JM, Salvador-Carulla L, Cabases J, et al. Utilization of mental health services and costs of patients with schizophrenia in three areas of Spain. Br J Psychiatry. 1998;173:334–340.
   PubMed Web of Science ®Google Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764–771.
   PubMed Web of Science ®Google Scholar
• Lavallee C, Maughn K, Gyanani A, et al. Real-world evidence investigation on healthcare utilization and cost among negative symptom patients and non-negative symptom patients in the USA. PMH25. Value in Health. 2019;22(suppl 2):S230.
   Google Scholar
• Sicras-Mainar A, Maurino J, Ruiz-Beato E, et al. Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study. BMC Psychiatry. 2014;14:225.
   PubMed Web of Science ®Google Scholar
• Knapp M, McCrone P, Leeuwenkamp O. Associations between negative symptoms, service use patterns, and costs in patients with schizophrenia in five European countries. Clinc Neuropsych. 2008;5(4):195–205.
   Google Scholar
• Steinert T, Krueger M, Gebhardt RP. Costs of treatment and outcome measures in schizophrenia. Eur J Psychol Assess. 1999;13:209–214.
   Google Scholar
• Nicholl D, Akhras KS, Diels J, et al. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin. 2010;26(4):943–955.
   PubMed Web of Science ®Google Scholar
• Wilson LS, Gitlin M, Lightwood J. Schizophrenia costs for newly diagnosed versus previously diagnosed patients. Am J Pharm Benefits. 2011;3(2):107–115.
   Google Scholar
• Pennington M, McCrone P. The cost of relapse in schizophrenia. Pharmacoeconomics. 2017;35(9):921–936.
   PubMed Web of Science ®Google Scholar
• Haynes VS, Zhu B, Stauffer VL, et al. Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study. BMC Psychiatry. 2012;12:222.
   PubMed Web of Science ®Google Scholar
• Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. Pharmacoeconomics. 2017;35(1):25–42.
   PubMed Web of Science ®Google Scholar
• Bobes J, Arango C, Garcia-Garcia M, et al. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71(3):280–286.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Werbeloff N, Caers I, et al. Negative symptoms in schizophrenia–the remarkable impact of inclusion definitions in clinical trials and their consequences. Schizophr Res. 2013;150(2–3):334–338.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Mucci A, Buchanan RW, et al. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664–677.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Levine SZ, Garibaldi G, et al. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137(1-3):147–150.
   PubMed Web of Science ®Google Scholar
• Foussias G, Agid O, Fervaha G, et al. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol. 2014;24(5):693–709.
   PubMed Web of Science ®Google Scholar
• Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull. 2006;32(2):234–237.
   PubMed Web of Science ®Google Scholar
• Weber S, Scott JG, Chatterton ML. Healthcare costs and resource use associated with negative symptoms of schizophrenia: a systematic literature review. Schizophr Res. 2022;241:251–259.
   PubMed Web of Science ®Google Scholar
• Sado M, Inagaki A, Koreki A, et al. The cost of schizophrenia in Japan. Neuropsychiatr Dis Treat. 2013;9:787–798.
   PubMed Web of Science ®Google Scholar
• Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry. 1994;165(S25):18–21.
   Google Scholar
• Ahn J, McCombs JS, Jung C, et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health. 2008;11(1):48–56.
   PubMed Web of Science ®Google Scholar
• Pesa JA, Doshi D, Wang L, et al. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. Curr Med Res Opin. 2017;33(4):723–731.
   PubMed Web of Science ®Google Scholar
• Sarlon E, Heider D, Millier A, et al. A prospective study of health care resource utilisation and selected costs of schizophrenia in France. BMC Health Serv Res. 2012;12:269–276.
   PubMed Web of Science ®Google Scholar
• Laidi C, Prigent A, Plas A, et al. Factors associated with direct health care costs in schizophrenia: results from the FACE-SZ French dataset. Eur Neuropsychopharmacol. 2018;28(1):24–36.
   PubMed Web of Science ®Google Scholar
• Hirjak D, Hochlehnert A, Thomann PA, et al. Evidence for distinguishable treatment costs among paranoid schizophrenia and schizoaffective disorder. PLoS One. 2016;11(7):e0157635.
   PubMed Web of Science ®Google Scholar
• Esposti LD, Sangiorgi D, Mencacci C, et al. Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study. BMC Psychiatry. 2014;14:282.
   PubMed Web of Science ®Google Scholar
• Cortesi PA, Mencacci C, Luigi F, et al. Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. BMC Psychiatry. 2013;13:98.
   PubMed Web of Science ®Google Scholar
• Esposti LD, Sangiorgi D, Ferrannini L, et al. Cost-consequences analysis of switching from oral antipsychotics to long-acting risperidone in the treatment of schizophrenia (provisional abstract). J Psychopathol. 2012;18(2):170–176.
   Google Scholar
• Arteaga Duarte C, Colin X, De Moor R, et al. Three-monthly long-acting formulation of paliperidone palmitate is a dominant treatment option, cost saving while adding QALYS, compared to the one-monthly formulation in the treatment of schizophrenia in France. Value Health. 2016;19(7):A378.
   Web of Science ®Google Scholar
• Dilla T, O'Donohoe P, Möller J, et al. Cost-effectiveness of long-acting olanzapine versus long-acting risperidone in patients with schizophrenia in Spain. Value Health. 2011;14(7):A292.
   Web of Science ®Google Scholar
• Davies A, Vardeva K, Loze JGJL, et al. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK. Curr Med Res Opin. 2008;24(11):3275–3285.
   PubMed Web of Science ®Google Scholar
• Tilden D, Aristides M, Meddis D, et al. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clin Ther. 2002;24(10):1648–1667.
   PubMed Web of Science ®Google Scholar
• Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184(4):346–351.
   PubMed Web of Science ®Google Scholar
• Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess. 2003;7(13):1–193.
   PubMedGoogle Scholar
• Rajagopalan K, Trueman D, Crowe L, et al. Cost- utility analysis of lurasidone versus aripiprazole in adults with schizophrenia. Pharmacoeconomics. 2016;34(7):709–721.
   PubMed Web of Science ®Google Scholar